Investment Rating - The report maintains a "Buy" rating for China Feihe (6186.HK) with a projected PE of 12, 10, and 9 times for the years 2025, 2026, and 2027 respectively, based on the market capitalization of HKD 39.5 billion [4]. Core Views - The company reported a revenue of HKD 9.151 billion for H1 2025, a decrease of 9.36% year-on-year, and a net profit attributable to shareholders of HKD 1 billion, down 46.66% [1]. - The decline in revenue is attributed to the company's proactive inventory reduction strategy, particularly in the infant formula segment, and the provision of fertility subsidies to consumers [2]. - The gross profit margin for H1 2025 was 61.58%, a decrease of 6.30 percentage points year-on-year, primarily due to increased costs of raw milk powder [3]. Summary by Sections Financial Performance - In H1 2025, revenue from dairy products and nutritional supplements was HKD 9.143 billion, down 9.08% year-on-year, while raw milk revenue fell by 79.82% to HKD 0.08 billion [2]. - Revenue from mainland China, the US, and Canada was HKD 9.041 billion, HKD 0.91 billion, and HKD 0.18 billion respectively, with year-on-year changes of -9.47%, +11.94%, and -30.69% [2]. - The company's other income and gains decreased by 37.4% to HKD 540 million, mainly due to reduced government subsidies and interest income [3]. Profitability - The net profit margin for H1 2025 was 10.93%, down 7.64 percentage points year-on-year, influenced by the decline in gross margin, reduced government subsidies, and increased administrative expenses [3]. - Administrative expenses rose by 4.7% to HKD 774 million, primarily due to increased employee compensation [3]. Future Projections - The company is expected to achieve net profits of HKD 3.007 billion, HKD 3.472 billion, and HKD 3.818 billion for the years 2025, 2026, and 2027, reflecting year-on-year growth rates of -15.78%, 15.48%, and 9.96% respectively [4].

Investment Rating - The report maintains a "Recommended" rating for China Feihe (06186.HK) with a target price of HKD 5.1 [1][4]. Core Views - The company reported a 9.36% year-on-year decline in revenue for H1 2025, totaling CNY 9.151 billion, and a 46.66% drop in net profit to CNY 1 billion. The interim dividend declared is HKD 0.1209 per share, amounting to CNY 1 billion [1][4]. - The company is facing significant operational pressure due to intensified competition and proactive inventory reduction, which has led to a decrease in market share [4]. - The gross margin for H1 2025 was 61.58%, down 6.3 percentage points year-on-year, primarily due to changes in sales structure and losses from raw milk powder [4]. - The company is implementing various measures to adjust operations, including inventory management and the introduction of new customized products, aiming for a recovery in performance [4]. Financial Summary - **Revenue Forecasts**: - 2024A: CNY 20.749 billion - 2025E: CNY 18.792 billion - 2026E: CNY 19.835 billion - 2027E: CNY 20.469 billion - Year-on-year growth rates: 5.6%, -9.4%, 5.5%, 3.2% [1][10]. - **Net Profit Forecasts**: - 2024A: CNY 3.570 billion - 2025E: CNY 2.190 billion - 2026E: CNY 3.001 billion - 2027E: CNY 3.384 billion - Year-on-year growth rates: 5.3%, -38.7%, 37.1%, 12.8% [1][10]. - **Earnings Per Share (EPS)**: - 2024: CNY 0.39 - 2025: CNY 0.24 - 2026: CNY 0.33 - 2027: CNY 0.37 [1][10]. - **Valuation Ratios**: - Price-to-Earnings (P/E) ratios for 2025E: 17 - Price-to-Book (P/B) ratios for 2025E: 1.4 [1][10]. Market Performance - The current share price is HKD 4.39, with a market capitalization of HKD 39.8 billion [2]. - The stock has experienced a 12-month high of HKD 6.80 and a low of HKD 3.34 [2]. Strategic Adjustments - The company is focusing on health-oriented strategies and actively promoting reforms to address operational challenges, including inventory adjustments and the launch of new products [4]. - The company aims to improve channel profitability and market presence through these strategic initiatives [4].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to inventory clearance and reduced government subsidies, but anticipates recovery in the second half of the year with the potential positive impact of fertility subsidies and improved operational efficiency through digital management tools [1][2]. Financial Performance - For 25H1, the company achieved revenue of 9.15 billion yuan and a net profit of 1 billion yuan, representing year-on-year declines of 9.4% and 46.7%, respectively, aligning with prior forecasts [1]. - The gross margin decreased by 6.3 percentage points to 61.6%, while the net profit margin fell by 7.6 percentage points to 10.9%, largely due to reduced government subsidies and losses from inventory adjustments [2]. - The company plans to distribute at least 2 billion yuan in dividends and repurchase up to 10% of its shares, using at least 1 billion yuan for this purpose [2]. Business Segments - Revenue from dairy products and nutritional products declined by 9.1%, while revenue from raw milk plummeted by 79.8% in 25H1, reflecting ongoing demand pressures in the infant formula sector [1]. - The company reported revenues of 9.04 billion yuan in mainland China, 90 million yuan in the U.S., and 20 million yuan in Canada, with year-on-year changes of -9.5%, +11.9%, and -30.7%, respectively [1]. Future Outlook - The company expects the inventory adjustment process to conclude by August 2025, with anticipated positive effects from fertility subsidy policies in the second half of the year [1]. - Revenue forecasts for 2025-2027 have been revised downwards to 19.91 billion, 21.20 billion, and 22.23 billion yuan, reflecting ongoing industry challenges and competitive pressures [2]. - The company aims to enhance operational efficiency through improved channel management and digital tools, which may lead to better profitability in the long term [2].

Core Viewpoint - HSBC Research projects that China Feihe (06186) will maintain a compound annual growth rate (CAGR) of 2.4% in revenue and 5.5% in earnings before interest and taxes (EBIT) from 2025 to 2028, driven by favorable government population policies [1][1][1] Financial Performance - For the interim period of 2025, China Feihe reported revenue of 9.15 billion yuan and a net profit of 1.03 billion yuan, with cash and cash equivalents amounting to 6.48 billion yuan, indicating a solid operational foundation [1][1][1] Shareholder Returns - Based on robust performance and strong cash flow, China Feihe plans to utilize no less than 1 billion yuan for share repurchases and anticipates distributing approximately 1 billion yuan in dividends for the interim period of 2025, with a total dividend distribution of no less than 2 billion yuan for the year 2025, enhancing earnings per share through active buybacks [1][1][1]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 5.23, while the closing price as of August 28 was HKD 4.36 [1][5]. Core Views - The company's revenue and net profit for the first half of 2025 were reported at RMB 9.15 billion and RMB 1 billion, respectively, reflecting a year-on-year decline of 9.4% and 46.7%, which aligns with the performance forecast [5][6]. - The company is undergoing a phase of inventory clearance, which is expected to continue until the end of August 2025, impacting revenue in the short term [5][6]. - The report anticipates a recovery in operations post-inventory clearance, with positive effects expected from fertility subsidies and increased dividend and buyback efforts [5][7]. Financial Performance Summary - For the first half of 2025, the gross margin decreased by 6.3 percentage points to 61.6%, and the net profit margin fell by 7.6 percentage points to 10.9% due to reduced government subsidies and inventory-related losses [7][8]. - The company plans to distribute at least RMB 2 billion in dividends for 2025 and intends to repurchase up to 10% of its total shares, amounting to at least RMB 1 billion [7][8]. - Revenue projections for 2025-2027 have been adjusted to RMB 199.1 billion, RMB 212.0 billion, and RMB 222.3 billion, reflecting a downward revision of 10%, 7%, and 7% respectively [8][12]. Earnings Forecast and Valuation - The expected earnings per share (EPS) for 2025, 2026, and 2027 are RMB 0.34, RMB 0.40, and RMB 0.46, respectively, with a corresponding price-to-earnings (PE) ratio of 14 times for 2025 [8][12]. - The report highlights that the company, as a leader in the infant formula industry, is expected to improve operational efficiency through enhanced channel management and digitalization efforts [7][8].

Core Insights - China Feihe reported a strong performance in its 2025 mid-year earnings report, with revenue reaching 9.15 billion yuan and net profit at 1.03 billion yuan, indicating robust operational fundamentals and financial resilience [1] - The company maintained its leading position in the infant formula market, achieving the highest market share and sales across all channels in the first half of 2025 [1] Financial Performance - Revenue for the first half of 2025 was 9.15 billion yuan [1] - Net profit for the same period was 1.03 billion yuan [1] - The company reported a strong cash flow of 6.48 billion yuan [1] Market Position - Feihe's infant formula products continued to dominate the market, securing the top market share and sales volume [1]

Core Insights - China Feihe reported a revenue of 9.15 billion RMB and a net profit of 1.03 billion RMB for the first half of 2025, showcasing a robust financial structure and strong cash flow [1] - The company emphasizes technological innovation as a core driver for growth, maintaining its leading market position in infant formula [2][3] Financial Performance - Revenue for the first half of 2025 reached 9.15 billion RMB, with a net profit of 1.03 billion RMB and cash and cash equivalents totaling 6.48 billion RMB [1] - The company plans to distribute approximately 1 billion RMB in dividends for the mid-2025 period, with a total dividend payout of no less than 2 billion RMB for the year [15] Market Position - Feihe maintains the number one market share and sales in the infant formula sector, supported by continuous investment in scientific research and innovation [2] - The company has achieved significant progress in overseas markets, generating approximately 110 million RMB in revenue from international operations in the first half of 2025 [8] Technological Innovation - Feihe has established a cross-national collaborative innovation network with over 20 top research institutions globally, focusing on brain development strategies [2] - The company launched a groundbreaking "fresh protein extraction technology" that enhances the quality and nutritional value of its products [2] Product Development - Feihe introduced the first domestic application-based human milk oligosaccharides (HMOs) database, providing a scientific basis for developing infant formula closer to Chinese breast milk [3] - The company’s star product, Xingfeifan Zhuorui formula, has shown active nutritional components (N-sugars) at twice the level of regular formula and a DHA absorption rate 6.4 times higher [6] Global Expansion - In North America, Feihe's Kingston factory received the first local infant formula production license, marking a significant milestone for "Chinese manufacturing" [8] - The company is expanding into Southeast Asia, starting with the Philippines, and plans to replicate its success in other potential markets like Vietnam and Indonesia [10] Social Responsibility - Feihe initiated a 1.2 billion RMB maternity subsidy program to support families during pregnancy, aiming to benefit over 800,000 newborn families [13] - The company has created 170,000 jobs and increased the income of 160,000 farmers through its "common prosperity chain" initiative [13]

Core Viewpoint - China Feihe (06186) demonstrated strong financial performance in its 2025 mid-year report, showcasing robust revenue and profit figures along with significant cash flow, indicating a solid operational foundation and financial resilience [1] Financial Performance - The company achieved a revenue of 9.15 billion RMB and a net profit of 1.03 billion RMB during the reporting period [1] - Cash flow reached 6.48 billion RMB, reflecting strong liquidity and operational efficiency [1] Market Position - Feihe maintained its position as the market leader in the infant formula sector, with continued dominance in both market share and sales volume [1] Innovation and Technology - The company is driving growth through hard technology innovation, having launched the "Milk Protein Fresh Extraction Technology" and the first comprehensive HMOs database in China, reinforcing its technological barriers [1] International Expansion - Feihe's international strategy is accelerating, with over 1,500 supermarkets in North America now carrying its products, representing a 270% year-on-year increase in overseas store count [1] - The company is also expanding into Southeast Asia, successfully entering the Philippine market [1] Shareholder Returns - The company announced a plan to invest 1 billion RMB in share buybacks and distribute approximately 1 billion RMB in interim dividends, with an expected total dividend distribution of no less than 2 billion RMB for 2025, aimed at boosting investor confidence [1] Social Responsibility - Feihe initiated a 1.2 billion RMB fertility subsidy program, responding to national policies and expected to benefit over 800,000 newborn families, demonstrating its commitment to social responsibility and long-term value creation [1]

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國飛鶴有限公司 | | 股份代號 | 06186 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至2025年6月30日止6個月之中期股息 | | | 公告日期 | 2025年8月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.1209 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.1209 HKD | | 匯率 | 1 HKD : 1 HK ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 China Feihe Limited 中國飛鶴有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6186） 截至二零二五年六月三十日止六個月 的中期業績公告 財務摘要 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月： – 3 – 中國飛鶴有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附屬公司 （統 稱「本集團」、「我 們」或「飛 鶴」）截至二零二五年六月三十日止六個月（「報 告 期 間」）之 未 經 審 核 綜 合 中 期 業 績，連 同 二 零 二 四 年 同 期 之 比 較 數 字。 – 1 – • 本集團的收益為人民幣9,150.5百 萬 元，同 比 減 少9.4%； • 本集團的毛利為人民幣5,634.9百 萬 元，同 比 減 少17.8%； • 本集團的期內溢利為人民幣 ...